PK IDIQ- Post-market Bioequivalence of Generic Drug Products
Past New Requirement Updated
- Agency
-
Food and Drug Administration
Department of Health and Human Services
- Solicitation expected
- Estimated value
- $20,000,000 to $50,000,000
- Set-aside
- No set-aside
Forecast facts
- Anticipated award
- NAICS code
- 923120 Administration of Public Health Programs
- Points of contact
-
- tbd@fda.gov
- Christopher Scott christopher.scott@fda.hhs.gov
Forecast details come from HHS's procurement forecast. Agencies' dates and values are estimates.
About this forecast
The Food and Drug Administration (FDA) is forecasting a post-market bioequivalence research contract for generic drug products, structured as an Indefinite Delivery/Indefinite Quantity (IDIQ) procurement. The solicitation is estimated to be released on July 1, 2026, with an anticipated contract award date of September 1, 2026, targeting the Administration of Public Health Programs (NAICS 923120). The primary objective appears to be conducting comprehensive post-market studies to evaluate the bioequivalence of generic pharmaceutical products.
While specific award values are not disclosed, the contract will likely involve complex pharmaceutical research and analysis work to be performed within FDA facilities or designated research environments. Christopher Scott (christopher.scott@fda.hhs.gov) is identified as the primary point of contact for this procurement, representing the Food and Drug Administration. Interested contractors should prepare for a competitive solicitation process that will require specialized expertise in pharmaceutical research, public health program administration, and generic drug product evaluation methodologies.
Forecast text
PK IDIQ- Post-market Bioequivalence of Generic Drug Products
On GovTribe
Work this forecast
- Track it in your pipeline
- Find teaming partners
- Similar forecasts
- Ask GovTribe AI about this forecast